OXiGENE (OXGN) and the FDA reach a deal on a special protocol assessment for the Phase 3 trial...

|By:, SA News Editor

OXiGENE (OXGN) and the FDA reach a deal on a special protocol assessment for the Phase 3 trial of its thyriod cancer drug zybrestat. Shares +14.8% AH.